Neuphoria Therapeutics Inc.
NEUP
$4.66
-$0.01-0.21%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -13.30K | 15.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -13.30K | 15.00M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -13.30K | 15.00M |
| SG&A Expenses | 1.69M | 2.16M | 1.87M | 2.03M | 1.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 827.30K | 2.35M | 5.65M | 5.82M | 3.03M |
| Operating Income | -827.30K | -2.35M | -5.65M | -5.84M | 11.97M |
| Income Before Tax | -539.90K | 1.83M | -9.94M | -9.15M | 11.18M |
| Income Tax Expenses | -34.80K | -34.80K | -34.80K | -266.60K | -81.20K |
| Earnings from Continuing Operations | -505.10K | 1.86M | -9.91M | -8.88M | 11.26M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -505.10K | 1.86M | -9.91M | -8.88M | 11.26M |
| EBIT | -827.30K | -2.35M | -5.65M | -5.84M | 11.97M |
| EBITDA | -661.60K | -2.18M | -5.49M | -5.67M | 12.14M |
| EPS Basic | -0.09 | 0.41 | -4.41 | -4.67 | 6.55 |
| Normalized Basic EPS | -0.06 | 0.42 | -2.77 | -3.09 | 4.07 |
| EPS Diluted | -0.09 | -0.77 | -4.41 | -4.67 | 6.55 |
| Normalized Diluted EPS | -0.06 | 0.42 | -2.77 | -3.09 | 4.07 |
| Average Basic Shares Outstanding | 5.41M | 4.54M | 2.25M | 1.90M | 1.72M |
| Average Diluted Shares Outstanding | 5.41M | 4.54M | 2.25M | 1.90M | 1.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |